Grand Rounds

Are ACE Inhibitors and ARBs Associated with Increased COVID-19 Susceptibility?

FavoriteLoading

BACKGROUND AND PURPOSE:

  • Hippisley-Cox et al. (Heart, 2020) used a large population study to investigate whether there is an association between ACE inhibitors and ARBs and COVID-19 disease susceptibility and progression

METHODS:

  • Prospective cohort study
  • Setting
    • General practices in England
  • Participants
    • Adults aged 20 to 99 years
  • Exposures
    • ACE inhibitors and ARB drugs
  • Study design
    • Cox proportional hazards models were used to derive adjusted hazard ratio
    • Results adjusted for confounders such as sociodemographic factors, concurrent medications and geographical region
  • Primary outcome
    • RT-PCR confirmed COVID-19
    • COVID-19 that resulted in ICU care

RESULTS:

  • 19,486 patients had COVID-19
    • Received ICU care: 1286
  • ACE inhibitors and ARBs were associated with a significantly reduced risk of COVID-19
    • ACE inhibitors
      • Adjusted HR 0.71 (95% CI, 0.67 to 0.74)
    • ARBs
      • Adjusted HR 0.63 (95% CI, 0.59 to 0.67)
  • Neither ACE inhibitors nor ARBS were associated with an increased risk of ICU care
    • ACE inhibitors
      • Adjusted HR 0.89 (95% CI, 0.75 to 1.06)
    • ARBs
      • Adjusted HR 1.02 (95% CI, 0.83 to 1.25)
  • The risk of COVID-19 disease associated with ACE inhibitors was higher in Caribbean and Black African groups vs white group | The risk of COVID-19 disease associated with ARBs was higher in the Black African group vs the white group

CONCLUSION:

  • ACE inhibitors and ARBs were associated with a reduced risk of COVID-19
  • ACE inhibitors and ARBS was not associated with an increased risk of ICU care
  • The authors state

Variations between different ethnic groups raise the possibility of ethnic-specific effects of ACE inhibitors/ARBs on COVID-19 disease susceptibility and severity which deserves further study

Learn More – Primary Sources:

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

FavoriteLoading

Related ObG Topics:

COVID-19, ACE Inhibitors and ARBs: Professional Guidance and Evidence Update
Cardiac Injury: A Feature of COVID-19
COVID-19 and NSAIDs: Is There Reason for Concern with Use of Ibuprofen?

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!